Type 2 immunity is critical for defense against cutaneous infections but also underlies the development of allergic skin diseases. We report the identification in normal mouse dermis of an abundant, phenotypically unique group 2 innate lymphoid cell (ILC2) subset that depended on interleukin 7 (IL-7) and constitutively produced IL-13. Intravital multiphoton microscopy showed that dermal ILC2 cells specifically interacted with mast cells, whose function was suppressed by IL-13. Treatment of mice deficient in recombination-activating gene 1 (Rag1 −/− ) with IL-2 resulted in the population expansion of activated, IL-5-producing dermal ILC2 cells, which led to spontaneous dermatitis characterized by eosinophil infiltrates and activated mast cells. Our data show that ILC2 cells have both pro-and anti-inflammatory properties and identify a previously unknown interactive pathway between two innate populations of cells of the immune system linked to type 2 immunity and allergic diseases. 
A r t i c l e s
The skin is the outermost barrier between the environment and internal organs that contains cells of the immune system deployed as sentinels that serve as a first line of defense against microbial attacks. The epidermis of mice has two relatively uniform populations of such cells, Langerhans cells and dendritic epidermal T cells (DETCs), whereas the dermis contains a large variety of leukocytes, including dermal dendritic cells (DDCs), macrophages, mast cells and αβ and γδ T cells. It is believed that most of the productive immune responses to invading microbes are initiated in the dermis, although the precise lineage relationships of dermal leukocyte subsets and their exact functions during homeostasis and disease are yet to be defined.
Type 2 cytokine-dependent responses are essential for protection against helminth infections but also underlie the development of inflammatory allergic diseases, such as atopic dermatitis 1 . Although overproduction of epidermis-associated innate cytokines, such as thymic stromal lymphopoietin (TSLP) 2 , has been associated with the development of cutaneous allergic sequelae, the cellular events in the skin that could be responsible for biasing subsequent immune responses to a T helper type 2 (T H 2; atopic) phenotype have not been identified. In particular, there is no information about whether an innate type 2 sensor is present in the dermis.
A class of innate lymphoid cells (ILCs), the group 2 ILCs (ILC2 cells) 3 , has been identified in fat-associated lymphoid tissue and mucosa-associated tissues (the respiratory and intestinal tracts) on the basis of their responsiveness to interleukin and the production of type 2 cytokines, the foremost being IL-13 (refs. 4-8) . Cells that belong to the ILC2 family include natural helper cells 7 , nuocytes 8 and innate helper 2 cells 9 . ILC2 cells are defined as lineage-negative (Lin − ) CD45 + CD90 + CD127(IL-7Rα) + ICOS + with variable expression of the stem-cell-factor receptor CD117 (c-Kit), the lineage marker Sca-1 and the IL-33 receptor ST2. Nuocytes have been shown to differentiate from common lymphocyte progenitors and to depend on the transcription factor RORα 10 . In adult mice, ILC2 cells are a rare population that expands in response to IL-25 or IL-33 or during helminth infection 8 and represent a chief source of IL-13, a pleiotropic cytokine that mediates a variety of effects, including suppression of cytokine production by monocytes 11 , mucus production by goblet cells and the recruitment of eosinophils by epithelial cells [12] [13] [14] . ILC2 cells can also produce IL-5, which has been linked to eosinophil recruitment, as well as IL-9 (ref. 15) , which is prominent during helminth infections 16, 17 and has been linked to atopic disease 18 . ILC2 cells have been shown to be involved in immunity to helminths as well as in allergic conditions such as asthma and chronic sinusitis 4, 5, 7, 8 but are also probably important for maintaining tissue homeostasis 6 . Despite such advances, very little is understood about the activity of ILC2 cells in situ, and it remains unclear what other cell types ILC2 cells interact with in vivo.
The same staining strategy also identified an equivalent population in the mesentery (Fig. 1c) that most probably corresponded to the natural helper cells described before 7 . However, unlike the mucosal populations, skin ILC2 cells uniquely expressed CD103 (Fig. 1d) , an integrin (α E β 7 ) expressed by some skin-resident leukocytes, particularly T cells 19 . Further phenotypic analysis of this population showed a lack of key markers of T cells and NK cells, together with expression of markers associated with ILC2 cells, notably the high-affinity IL-2 receptor CD25, Sca-1 and ST2 (Supplementary Fig. 2) . In contrast to the ILC2 populations described in other tissues, skin ILC2 cells did not have detectable expression of CD117 (c-Kit), but they did express the IL-25 receptor IL-17BR ( Supplementary Fig. 2 and data not shown). We therefore called these 'dermal ILC2 cells' (dILC2 cells). These CD45 + CD3 − CD2 − CD90 hi cells were detectable in other tissues, including blood and skin-draining lymph nodes ( Fig. 1e and data not shown), but their abundance in the total leukocyte pool was very low for these tissues, particularly relative to their abundance in the dermis, where dILC2 cells constituted 5-10% of all CD45 + cells isolated (Fig. 1f) . We concluded that the dermis contains an abundant, phenotypically distinct population of ILC2 cells.
Developmental requirements for dILC2 cells in vivo
We next determined the developmental requirements of dILC2 cells in vivo. As many skin cells, including Langerhans cells, DETCs and dermal 
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A r t i c l e s γδ T cells, are largely or partially radioresistant 19 , we first addressed the radiosensitivity of dILC2 cells. We sublethally irradiated CD45.1 + recipient mice and reconstituted them with CD45.2 + bone marrow. At 8 weeks after irradiation, dILC2 cells were predominantly of donor origin, in contrast to radioresistant CD3 hi DETCs (Fig. 2a) . As nuocytes have been shown to be derived from common lymphoid progenitors 10 , we determined whether dILC2 cells were dependent on the transcription factor Ikaros, which is essential for the generation of common lymphoid progenitors and subsequent development of 'lymphoid' cells 20 . We made use of Ikzf1 L/L mice, in which the β-galactosidase reporter is inserted into the locus encoding Ikaros (Ikzf1) 21 . Ikzf1 L/L mice are not completely deficient in Ikaros but are nevertheless unable to achieve wild-type Ikaros activity. To address the reliance of dILC2 cells on Ikaros, we sublethally irradiated wild-type (CD45.1 + ) mice and reconstituted them with a 50:50 mixture of mT/mG bone marrow (which in these experiments had ubiquitous expression of membrane-targeted red fluorescent protein (RFP) Tomato (mT) 22 and wild-type bone marrow ('control chimeras') or a 50:50 mixture of mT/mG bone marrow and Ikzf1 L/L bone marrow ('test chimeras') and examined the chimeric recipients 6-8 weeks later. Test chimeras had a significantly lower frequency of donor-derived (CD45.2 + ) mT − dILC2 cells than did control chimeras (Fig. 2b) , which indicated that dILC2 cells were dependent on Ikaros for their development, consistent with a lymphoid origin for these cells.
To further explore the developmental and homeostatic requirements of dILC2 cells, we evaluated these cells in various genetically deficient mice. We found dILC2 cells in mice deficient in recombinationactivating gene 1 (Rag1 −/− ), mice of the nonobese diabetic, severe combined immunodeficiency strain and thymus-deficient Foxn1 nu/nu (nude) mice (Fig. 2c, Supplementary Fig. 3 and data not shown), which confirmed that they were not a T cell population and did not require the thymus for their development. We found no dILC2 cells in mice deficient in the kinase Jak3 (Jak3 −/− ) 23 (Fig. 2c,d) , which indicated a requirement for signaling through the common γ-chain for their development or maintenance. Although dILC2 cell numbers were unaffected in mice deficient in IL-15 or IL-2 (Fig. 2c,d and data not shown), they were absent from IL-7-deficient skin (Fig. 2e) . Collectively these data indicated that dILC2 cells shared the same developmental requirements that nuocytes 10 and natural helper cells 7 have. Of note, Rag1 −/− mice and other T cell-deficient mice had more dILC2 cells than did wild-type mice ( Fig. 2d and Supplementary Fig. 3 ), possibly due to the greater availability of IL-7. Given the apparent propensity of nuocytes to undergo population expansion in response to IL-25 (ref. 8) , we also determined whether dILC2 cells were present in Il25 −/− mice. Lack of IL-25 had no effect on dILC2 cell numbers (Fig. 2f) , which indicated that IL-25 alone was dispensable for the homeostasis of dILC2 cells in the steady state. (Fig. 3a) . In 4C13R mice, cellular expression of Il4 and Il13 is reported without an effect on the endogenous production of IL-4 and IL-13. We found that 4C13R mice were healthy and viable and had a robust immunoglobulin E (IgE) response to infection with Nippostrongylus brasiliensis (Fig. 3b) , and AmCyan and dsRed fluorescence was readily detectable in 4C13R T cells cultured under T H 2-inducing conditions (data not shown).
When we examined the skin of 4C13R mice, we found that dsRedexpressing cells were exclusively CD45 + CD90 hi cells that were mostly CD3 − NK1.1 − dILC2 cells and some epidermal CD3 hi DETCs; the latter had lower expression of Il13-dsRed than did dILC2 cells ( Fig. 3c and data not shown). Il13-dsRed expression by dILC2 cells was unaffected in Il25 −/− mice (Fig. 3d) . Furthermore, we consistently detected IL-13 protein in all wild-type skin samples but found significantly less IL-13 protein in Il7 −/− mice ( Fig. 3e) , which indicated that dILC2 cells produced IL-13 in the steady state.
In contrast to their expression of Il13-dsRed, dILC2 cells from 4C13R mice did not express AmCyan (Fig. 3f) , which indicated that these cells did not produce IL-4 in the naive state. We found that dILC2 cells from mice with sequence encoding enhanced green fluorescent protein (eGFP) knocked in to one Il4 allele (Il4 +/gfp ) 25 to report Il4 expression were similarly eGFP − (Fig. 3g) . As it has been demonstrated that human ILC2 cells are able to produce IL-4 in response to TSLP in vitro 26 , we assessed whether dILC2 cells might similarly respond to TSLP in vivo. We examined eGFP expression by dILC2 cells from Il4 gfp/gfp mice after topical application of the vitamin D analog MC903, which has been shown to induce TSLP expression by skin keratinocytes 27 . We found more production of TSLP in MC903-treated ears than in vehicle-treated control ears (Fig. 3h) . After exposure to MC903, a small but reproducible population of dILC2 cells from TSLP receptor-sufficient mice expressed Il4-eGFP, but dILC2 cells from TSLP receptor-deficient mice did not (Fig. 3i) . IL-4 protein was not detectable in MC903-treated skin (data not shown), whereas IL-13 production by dILC2 cells was greater in MC903-treated skin than in vehicle-treated control skin, although this did not reach statistical significance ( Supplementary Fig. 4 ). We concluded that dILC2 cells produced IL-13 but not IL-4 in the naive state but generated IL-4 under defined inflammatory conditions.
Visualization of dILC2 cells in vivo
To visualize dILC2 cells in situ, we made use of mice with sequence encoding eGFP knocked in to one Cxcr6 ('Bonzo') allele (which encodes the chemokine receptor CXCR6; Cxcr6 +/gfp mice) 28 . In these mice, various lymphoid populations express eGFP, including some T cell subsets and RORγt + ILCs 29 . Flow cytometry of Lin − Sca-1 + natural helper cells 7 in the mesentery of Cxcr6 +/gfp mice demonstrated bright fluorescence in approximately 50% of these cells (Fig. 4a) . In the skin, almost all dILC2 cells expressed eGFP (Fig. 4b) . The ease with which eGFP + cells can be imaged in the skin of Cxcr6 +/gfp mice 19 enabled us to determine that density of dILC2 cells in Cxcr6 +/gfp mouse skin was 50-100 cells per mm 2 (Fig. 4c) .
To visualize dILC2 cells exclusively, we exploited their radiosensitivity and generated mixed-bone marrow chimeras by injecting Rag1 −/− Cxcr6 +/gfp bone marrow plus Rag1 +/+ GFP − mT + mT/mG bone marrow into irradiated wild-type recipient mice. We also generated 
npg
A r t i c l e s control chimeras by injecting irradiated recipients with a mixture of a small number of Cxcr6 +/gfp bone marrow cells with a large number of nonfluorescenct Rag1 −/− bone marrow cells, so that eGFP expression was restricted mainly to donor-derived T cells (data not shown). Flow cytometry confirmed that eGFP expression in the skin of recipient mice was confined to CD90 hi CD3 − CD2 − dILC2 cells, with only a minor contribution from CD3 − CD2 + NK cells (Fig. 4d) . We found that eGFP + dILC2 cells were readily detectable by multiphoton microscopy (Fig. 4e) , by which they showed a distinct migratory phenotype (Supplementary Video 1) . In contrast to the movement of cutaneous T cells, the average speed of dILC2 cells rarely exceeded 5 µm/min and was characterized by brief migratory periods followed by extended pauses (Fig. 4f and Supplementary  Video 2) . Thus, whereas the instantaneous speed of dILC2 cells was able to exceed 10 µm/min (Fig. 4g) , their average speed was similar to that of migratory DDCs 30 . The total displacement of dILC2 cells within a 15-minute time frame was also attenuated relative to that of the faster T cells (Fig. 4h) , whereas their mean meandering indices were almost identical (Fig. 4i) . These data demonstrated that despite their lower migratory speed, dILC2 cells nevertheless patrolled their local environment, consistent with a potential immunosurveillance function.
The presence of donor-derived mT-expressing cells in the mixed chimeras described above enabled us to address whether dILC2 cells interacted with radiosensitive leukocytes in the skin, particularly dermal macrophages and DCs (Fig. 4e) . Despite the high prevalence of mT + mT/mG bone marrow-derived antigen-presenting cells (APCs) in the ears of mixed chimeras, the interactions of dILC2 cells with those cells were infrequent and transient (Supplementary Videos 3  and 4) . Similarly, in triple chimeras generated by a combination of the mixed chimeras described above with the inclusion of bone marrow from CD11c-eYFP mice (which express enhanced yellow fluorescent protein (eYFP) from the gene encoding the common DC marker CD11c) for the visualization of DDCs, we did not observe Although we did not observe many interactions of dILC2 cells with APCs, the frequent stationary status of dILC2 cells nevertheless suggested that these cells did form stable contacts with another, presumably radioresistant cell population. Although that population could have included nonhematopoietic cells such as endothelial cells and fibroblasts, we were particularly interested in determining whether dILC2 cells were interacting with mast cells, given their role as an effector population in type 2 immune responses 31 and their resistance to irradiation (data not shown). To explore that possibility, we exploited the observation that Brainbow mice (with transgenic expression of a set of fluorescent proteins) 32 can be used as mast-cell reporter mice. We found not only expression of RFP (mT) in central and peripheral neurons in Brainbow mice but also RFP expression by some skin leukocytes (Fig. 5a) , including a population of RFP dim MHCII hi migratory DDCs and a nonmigratory population of predominantly perivascular RFP hi MHCII lo cells (Fig. 5b and  Supplementary Video 6) . Phenotypic analysis by flow cytometry demonstrated that these RFP hi cells were CD11b lo FcR1 + c-Kit + mast cells (data not shown), a result confirmed by the coexpression of RFP and eGFP in the progeny of Brainbow mice crossed with c-Kit-eGFP mast-cell reporter mice 33 (Fig. 5c) .
To determine whether dILC2 cells interacted with mast cells in vivo, we generated Brainbow Cxcr6 +/gfp mice and assessed their skin by multiphoton microscopy. We observed eGFP + cells in close proximity to RFP hi mast cells in these mice (Fig. 5d) . Those apparent interactions often lasted the entire recording session of 10-30 min Video 7) . To visualize dILC2 cells exclusively, without the presence of eGFP + T cells, we generated mixed-bone marrow chimeras by injecting Rag1 −/− Cxcr6 +/gfp bone marrow together with Rag1 +/+ GFP − bone marrow into irradiated Brainbow mice. As before, eGFP expression was restricted mainly to dILC2 cells (Fig. 5e) , whereas RFP expression was restricted to radioresistant mast cells. Intravital multiphoton imaging of these mice demonstrated not only that dILC2 cells migrated in close proximity to skin-resident mast cells ( Fig. 5f and Supplementary Videos 8 and 9) but also that dILC2 cells formed stable interactions with mast cells that lasted over 20-30 min (Fig. 5g and Supplementary Video 10) . Despite those sustained interactions, mast cells did not seem to be important for the occupation by and/or survival of dILC2 cells in the skin, as both the frequency and absolute number of dILC2 cells in the skin of mast cell-deficient B6-Kit W−sh/W−sh and WBB6F 1 -Kit W/W−v mice 34 did not differ from that of their respective control counterparts (Fig. 5h,i) .

A r t i c l e s (Supplementary
To determine how interactions between dILC2 cells might affect mast-cell biology, in particular the role of ILC2 cell-produced cytokines such as IL-13 and IL-9, we used a well-established in vitro model in which we measured IgE-dependent release of IL-6 and tumor-necrosis factor (TNF) by presensitized bone marrow-derived mast cells in the presence or absence of recombinant IL-13 or IL-9 (ref. 35) . Coincubation with IL-13 had a dose-dependent suppressive effect on the IgE-dependent release of cytokines by mast cells (Fig. 5j,k) . This suppression was specific, as coincubation with IL-9 conversely enhanced the production of IL-6 and TNF achieved by the same protocol (Supplementary Fig. 5 ). These data suggested that dILC2 cells had the potential to modulate mast-cell function through the production of IL-13.
IL-2-induced activation and proliferation of ILC2 cells in vivo
We sought to address the function of dILC2 cells in vivo. Although antibody-depletion approaches have been used successfully to evaluate the role of lung ILC2 cells in vivo 4, 36 , dILC2 cells seemed resistant to such strategies, as treatment with anti-CD90.2 or anti-CD25 did not result in the depletion of dILC2 cells in naive Rag1 −/− mice, even when splenic ILC2 cells were effectively cleared (Supplementary Fig. 6 ). We therefore sought to activate dILC2 cells directly in vivo to stimulate cytokine production. In contrast to NK cells and NKp46 + ILCs, ILC2 cells were unique in their expression of CD25 (Supplementary Fig. 7 ) and were the main CD25-expressing hematopoietic population in Rag1 −/− mice. As ILC2 cells have been shown to respond to IL-2 in vitro by producing IL-5, IL-9 and IL-13 (refs. 4,15,36) , we assessed whether IL-2 might also activate these cells in vivo by injecting Rag1 −/− mice with complexes of IL-2 and JES6-1 (a monoclonal antibody specific for IL-2) every second day for 1-3 weeks. Coadministration of IL-2 plus JES6-1 has been shown to selectively expand populations of CD25-expressing regulatory T cells in wild-type mice without activating cells such as NK cells that express the low-affinity IL-2 receptor 37 . After 2 weeks of such treatment, splenic ILC2 populations were expanded approximately fivefold in Rag1 −/− mice (Fig. 6a) , which indicated that IL-2 stimulated the proliferation of these cells. As expected, NK cells were unaffected (Fig. 6b and data not shown) . IL-2-expanded ILC2 populations had an activated phenotype, characterized by higher surface expression of CD25, ICOS, the activation marker CD69 and ST2, whereas the expression of some adhesion molecules (integrin β 7 and CD49d) was downregulated ( Fig. 6c and Table 1 ).
In the skin, the population expansion of dILC2 cells in response to IL-2-JES6-1 was much greater, with approximately tenfold greater absolute numbers after 2 weeks of treatment (Fig. 7a) . To visualize these cells, we treated Rag1 −/− Cxcr6 +/gfp mice with IL-2-JES6-1 for 2 weeks and then assessed the skin by multiphoton microscopy. We found many more Cxcr6-eGFP + dILC2 cells that were located mainly in close proximity to blood vessels (Fig. 7b) . Intravital imaging of these mice showed that activated dILC2 cells had the same heterogeneous migratory phenotype observed in the steady state, such that some dILC2 cells migrated but a large proportion remained stationary throughout the imaging period (Supplementary Video 11) .
Of note, we routinely observed vascular leakage of Evans blue when imaging IL-2-treated mice, indicative of inflammation (Supplementary Fig. 8a ). We therefore assessed the cytokine profile of skin from IL-2-treated mice and found more production of IL-5 and IL-13 protein, consistent with the population expansion and activation of dILC2 cells (Fig. 7c) , but also more inflammatory cytokines such as IL-6, TNF and CXCL1 (Fig. 7d) . We did not detect 
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A r t i c l e s the higher concentrations of IL-5 and IL-13 were due to more production of these cytokines by dILC2 cells, we sorted CD45 + CD90 hi CD2 − dILC2 cells from untreated and IL-2-treated Rag1 −/− mice and examined the abundance of Il5 and Il13 mRNA by quantitative RT-PCR. The expression of both Il13 and Il5 by dILC2 cells was much higher after treatment with IL-2-JES6-1, which indicated that IL-2-expanded dILC2 populations were functionally distinct from steady-state dILC2 cells, whereas the expression of Gata3 (which encodes the transcription factor GATA-3) 26,38 remained unchanged (Fig. 7e) .
We observed that over 50% of Rag1 −/− mice spontaneously developed clinically overt inflammatory skin lesions within 2-3 weeks of treatment with IL-2-JES6-1, particularly on or around the ears, eyes, mouth and tail (Fig. 7f and data not shown) . Histologically, these lesions showed epidermal hyperplasia, dermal thickening and extensive influx of eosinophils and neutrophils throughout the dermis and epidermis (Fig. 7g,h and Supplementary Fig. 8c) . Additionally, skin mast cells had a degranulated morphology in IL-2-treated skin (Fig. 7i) , particularly in regions with leukocyte infiltration (Supplementary Fig. 8d ). We concluded that IL-2-activated dILC2 cells promoted cutaneous inflammation, mediated at least in part by enhanced production of IL-5 and recruitment of eosinophils.
DISCUSSION
The skin is important for the early recognition of infection or environmentally derived antigens and for the appropriate bias for development into the T H 1, T H 2 or T H 17 subset of helper T cells; these processes are critical for resolution of the challenge. Furthermore, given the link of type 2 immunity to many important allergic and parasitic diseases, better understanding of the regulatory cues involved in its generation is imperative. In contrast to the well-established type 1-initiating cells in the dermis, such as IL-12-producing migratory DDCs and IL-17 producing γδ T cells 19 , the existence of an equivalent dermal leukocyte subset that drives downstream T H 2 immunity has remained speculative. Type 2 cytokine-producing ILC2 cells in the lung and gut have emerged as early responders after systemic parasitic infection and have also been linked to the pathogenesis of allergic diseases such as asthma 4, 24 . Here we have identified a previously unknown population of skin-resident CD103 + dermal ILC2 cells. In contrast to the previously described ILC2 cells in mucosa-associated tissues, we have demonstrated that the dermal ILC2 were abundant in the naive state and constitutively produced IL-13, but after activation they were also able to undergo population expansion and switch to a proinflammatory phenotype characterized by enhanced production of IL-5. The dILC2 cells were responsive to TSLP and were able to express Il4, which further emphasizes their likely importance as a type 2 sensor in the skin.
The nearly exclusive production of IL-13 in the skin by dILC2 cells may have relevance for atopic skin conditions, given the evidence that IL-13 has a major role in allergic inflammation, including atopic dermatitis 39 . Although the steady-state production of IL-13 by dILC2 cells would indicate a homeostatic function for this cytokine, it is nevertheless conceivable that dILC2 cell-derived IL-13 also has a role in atopic disease under more pathological conditions, particularly when the cytokine has better access to other cell populations such as endothelial cells and keratinocytes 40 .
It remains unclear whether dILC2 cells are a subset of circulating ILC2 cells 9 or whether they are a permanent skin-resident population. In the former case, ILC2 cells would seem to be highly skin trophic, given their greater abundance in the dermis than in blood or other organs. Indeed, we estimate that there are more dILC2 cells in two mouse ears than can be found in the entire spleen. Thus, ILC2 cells are not as rare as believed but do have a greater propensity for nonlymphoid tissues, particularly the skin. The greater prevalence of dILC2 cells in Rag1 −/− mice and much lower abundance in Il7 −/− mice suggests that ILC2 cells compete with T cells for IL-7, analogous to the greater prevalence of NK cells in Rag1 −/− mice due to improved IL-15 bioavailability 41 .
An important aspect of the function of leukocytes is their migratory activity and interactions in intact tissues. Our in vivo imaging experiments have shown that despite their developmental and phenotypic similarities, dILC2 cells differed considerably from T cells in their activity in the skin. The dILC2 cells characteristically migrated in bursts, followed by extensive pauses. These periods of migratory arrest seemed to result from encounters with skin-resident mast cells. The physical proximity of these two cell types supports the idea that ILC2 cells can directly influence mast-cell function and vice versa and that such influence need not be restricted to secreted cytokines but could result from receptor-ligand interactions. Thus, intravital imaging has identified an unexpected partnership between two type 2 cells of the immune system in vivo that is probably important in both steady-state and inflammatory conditions. Finally, we have demonstrated that ILC2 cells underwent direct activation and population expansion after treatment in vivo with IL-2-anti-IL-2 complexes, which enabled us to directly compare the phenotype of steady-state ILC2 cells with that of activated ILC2 cells in vivo and to assess the effect of the stimulation of dILC2 cells on cutaneous inflammation. We found that in vivo-stimulated ILC2 cells had a distinct phenotypic signature characterized by a greater abundance of CD25, ICOS and ST2 at the surface. In the skin, activated dILC2 cells produced much more IL-5, which resulted in eosinophil recruitment and predisposed the mice to spontaneous dermatitis. The occurrence of spontaneous lesions in sites routinely exposed to body fluids (tears and/or saliva) or minor trauma (ears and tail) is consistent with the existence of an external trigger, which presumably initiates a cascade of immunological events after keratinocyte activation.
The relevance of the responsiveness of ILC2 cells to IL-2 in immunocompetent mice requires additional investigation. It is likely that ILC2 cell function in vivo is regulated at least in part by T cells, as the main source of IL-2 in wild-type mice is activated T cells and the bioavailability of IL-2 is in turn influenced by the number of regulatory T cells 42 . By extension, ILC2 cells could represent an important downstream effector mechanism of the adaptive immune response. Indeed, evidence indicating that the population expansion of ILC2 cells during helminth infection depends on T cells has already been reported 8 , although IL-2 was not suggested as the underlying mechanism. In any case, our data have demonstrated that activation of dILC2 cells by IL-2 alone was sufficient to promote cutaneous inflammation and that these cells represented a potent effector population under the appropriate conditions.
The distinct phenotypic and functional differences between untreated and IL-2-treated dILC2 cells demonstrated that these cells had at least two functionally distinct states in vivo. In the steady state, dILC2 cells probably took on an immunoregulatory role in which dILC2 cell-produced IL-13 served to moderate mast cell activity. In contrast, once stimulated, dILC2 cells became proinflammatory and were able to promote eosinophil influx and mast-cell activation.
Together, these data demonstrate that dILC2 cells represent an abundant, phenotypically unique population of group 2 innate lymphoid cells in the skin with an important role in the regulation of cutaneous inflammation. These findings may be of relevance to various inflammatory skin conditions in which eosinophil recruitment is a defining feature, including atopic skin disease and parasitic infection.
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